RESEARCH ARTICLE

THE ROLE OF HYBRID BRACHYTHERAPY IN MANAGEMENT OF LOCALLY ADVANCED CERVICAL CANCER: DOSIMETRIC STUDY AND INITIAL RESULTS

M. Hommadi, H. Bakkali, O. Houessou, M. Benlemlih, T. Elmorjani, N. Bendahou, I. Lahdiri, S. Boutayeb, S. El Mejjaoui, H. EL Kacemi, T. Kebdani and N. Benjaafar
Department of Radiotherapy, The National Institute of Oncology, Rabat, Morocco.

Manuscript Info

Received: 25 November 2020
Final Accepted: 28 December 2020
Published: January 2021

Key words:
Cervical Cancer, Hybrid Brachytherapy, Utrecht Applicator

Abstract

Purpose: The aims of this study were to investigate the clinical feasibility and to report our preliminary treatment outcomes of combined intracavitary/interstitial brachytherapy (IC/IS BT), using a hybrid applicator and magnetic resonance imaging (MRI) based treatment planning in patients with locally advanced cervical cancer.

Materials and Methods: Between January 2017 and December 2018, eight patients with locally advanced uterine cervical cancer were treated with primary radiation therapy including hybrid BT. Patients with distant metastasis other than para-aortic lymph node spread were excluded from this study. A hybrid applicator for guidance of parametrial needles was used to perform high-dose-rate brachytherapy (HDR BT) with MRI based treatment pre-planning. Parametrial extent of the disease or large residual disease in these patients was judged to exceed the coverage limit of intracavitary brachytherapy alone. The number of needles, chosen guiding holes through the ovoids, and insertion depths were based on the extent of residual disease. We investigated the dosimetric gain by comparing the clinical IC/IS optimized plan (IC/IS clinical) with an additionally generated optimized plan without needle use (IC study).

Results: The clinical use of the hybrid applicator system proved to be feasible in all 32 treatment fractions. The applicator Fletcher interstitial 6mm or Utrecht interstitial consists of the IC tandem and two ovoids that serves as a template for needle insertion. MRI pre-planning was performed the week before the implant in 5 cases and the day of application with applicator in place in 3 cases. Four to eight needles were placed per fraction, and overall a total of 152 needles were used. Significant differences in (IC/IS) plan and (IC study) plan were derived for dose application to the target volume; D90 high-risk clinical target volume (D90 CTV HR) was 90.1Gy in (IC/IS clinical) plan vs 85.36 Gy in (IC study) plan with an average gain of 4.74 Gy. Likewise, sparing of organs at risk (OAR) differed significantly for bladder D2cc: 82.5 Gy (IC/IS clinical) vs 95.7 Gy (IC study) and rectum D2cc: 65.5 Gy (IC/IS clinical) vs 67.8 Gy (IC study). With an average follow-up of 27.25 months (range 18–34 months): no patient experienced local relapse, three patients experienced distant metastasis two of them died.

Corresponding Author: Hommadi Mouhcine
Address: Department of Radiotherapy, The National Institute of Oncology, Mohammed V University Rabat, Morocco.
no acute complications such as bleeding or organ penetration occurred due to needle placement, one patient developed recto-vaginal fistula. 

**Conclusions:** Our preliminary clinical experience indicates that combined intracavitary and interstitial MRI based brachytherapy in patients with significant residual disease extending up to the distal third of parametriaafter externalbeam therapy is feasible and allows excellent local control and a low rate of morbidity.

---

**Introduction:**

The standard of care for advanced cervical cancer is considered to be external-beam radiotherapy (EBRT) with concomitant cis-platinum based chemotherapy, followed by brachytherapy (BT) boost (1–5). Intracavitary BT techniques are widely used, with encouraging local control rates of 75% to 95% for small tumors (6). In cases of locally advanced disease, currently available intracavitary applicators often lead to inadequate target coverage and dose inhomogeneity for the lateral tumor parts. Local control rates in these patients remain low, ranging between 45% and 80% (6). Large tumors with distal parametrial involvement at diagnosis, insufficient response, and/or unfavorable topography after radio chemotherapy represent a therapeutic challenge for the radiation oncologist.

MRI-based planning was implemented for BT of cervical cancer because it has been proven to be highly appropriate to assess the tumor size and configuration (7), thus ensuring ideal tumor delineation and identification of high and intermediate-risk areas for local recurrence, based on the recommendations of the GYN GEC ESTRO BT committee, a standardized terminology has been implemented (8).

The concept of image-guided adaptive brachytherapy (IGABT) requires MRI of the tumor on the day of BT with an MRI-compatible BT applicator in place for assessment of tumor extension and localization of organs at risk (OAR). However, the treatment of larger and/or irregular-shaped tumors proves challenging. The dose distribution is limited by the doses applied to the OAR, such as the bladder, the sigmoid colon, the small intestines, and the rectum. A technical solution to the problem of irregular vertical extension of the tumor (e.g., in cases of parametrial infiltration) is the implementation of interstitial (IS) BT complementing the intracavitary (IC) BT using a hybrid applicator system (IC/IS). Several devices have successfully been adopted to conquer these shortcomings such as the Vienna applicator (tandem-ring), and the Utrecht applicator (tandem-ovoid) are examples of MRI-compatible applicators that can be used for combined (IC/IS) BT. Through holes in the ring or ovoids, which serve as a template, additional needles can be inserted. In a further development, recently the Venezia applicator (Elekta, Sweden) was introduced, allowing for even more degrees of freedom for even more advanced tailoring of dose distribution.

In this study we present data from the first 8 patients treated with the hybrid applicator in our department. We investigated the benefit of the combined IC/IS approach over the intracavitary approach alone and analyzed the clinical use of the needles.

**Materials and Methods:**

**Patients**

Between January 2017 and December 2018, a total of 8 patients with biopsy proven advanced cervical cancer not eligible for surgical therapy underwent curative intended chemoradiotherapy followed by BT using a hybrid applicator at the National Institute of Oncology of Rabat. The IC BT using the intrauterine tandem and two ovoids was complemented by interstitial needles. Staging was performed using thoraco-abdominal CT and pelvic MRI, as well as cystoscopy or rectoscopy, in cases of suspect organ infiltration.

**Chemoradiotherapy**

A planning CT scan was obtained with a slice thickness of 5 mm, with the application of intravenous contrast. Target volume delineation, treatment planning, and dose concepts were made according to the GEC-ESTRO recommendations (9). The clinical target volume included the primary tumor, the uterus the vagina the parameters, the internal iliac, external iliac, common iliac, obturator, and presacral lymph node regions. In cases of positive para-aortal lymph nodes, the para-aortic lymph node region was included in the CTV, 1cm was added to performe
PTV The prescribed dose was 46 Gy in 23 fractions to the primary tumor and the lymphatic pathways; in case of lymph nodal involvement, a boost of 10 to 20 Gy was applied. External beam radiotherapy (EBRT) was delivered by conformal radiotherapy on an Elekta Synergy Linac with weekly image guidance. Cisplatin was given intravenously once a week with a dose of 40 mg/m$^2$ of body surface area.

**Applicator**
The Utrecht Interstitial CT/MRI Applicator (image 1) has been specifically developed for combined IC/IS treatment for cervical cancer, with a combination of intracavitary and interstitial brachytherapy. Its design is based on the Fletcher CT/MRI applicator, and uses the ovoids as a template for interstitial needle placement. A needle guiding system, consisting of guiding tubes anchored in drilled holes through the ovoids, is used for needle placement (image 2). Each ovoid (having different sizes with 20, 25, or 30 mm of distance between the source channels) contains five needle holes in a 15 angle so that the needles are more or less parallel to the tandem. As many as 10 needles can be inserted, and insertion depth is variable. Through the combination of intracavitary and interstitial functionality, optimally conformal cervical and parametrial dose coverage can be achieved.

**Imaging, contouring, treatment planning, and dose reporting**
Combined (IC/IS BT) was conducted after completion of EBRT with a planning aim to the high-risk clinical target volume (HR-CTV) with a biologically equivalent dose of 90-95 Gy ($D_{90}$) in four BT sessions. MRI was obtained before initial treatment and during the last week of EBRT to assess treatment response (image 3). Preplanning for BT was based on tumor anatomy assessed by clinical examination and MRI. The extension of the cervical tumor and the flexion of the cervix were measured to determine the choice of the IC applicator and the ovoids. An estimate of the vertical extension, including infiltration of the parametria, was conducted to determine the number, position and the depth of interstitial needles.

BT was applied as HDR-BT in four fractions within two implants, once a week. The intra uterine utrecht applicator was positioned on epidural anesthesia, using ultrasound guidance. To verify correct positioning of interstitial needles, a planning CT was obtained and adjustments of needle position were made in the following application if required. With the hybrid applicator in place, an MRI was obtained for BT treatment planning on a 3 Tesla MRI (image 4). All patients followed a bowel preparation and bladder filling protocol to minimize internal organ motion. A planning CT with OAR delineation for dose optimization was performed for every single treatment fraction.

The target volumes: gross tumoral volume (GTV), HR-CTV, and intermediate-risk CTV (IR-CTV) were delineated according to GEC-ESTRO recommendations using an Oncentra Brachy treatment planning software (Elekta, Sweden). OARs such as rectum, bladder, sigmoid colon, and small intestines were defined. The EQD2 of all BT fractions and EBRT fractions were calculated, an $\alpha/\beta$ of 10 Gy was assumed for target volume and $\alpha/\beta$ of 3 Gy was used for OAR.

**Plan comparison**
To investigate the dose and dose distribution advantages of the applied optimized IC/IS treatment plan, we generated an additional treatment plan (ICstudy). The ICstudy plan was optimized by changing the source dwell position and dwell times of the tandem and ovoid only, leaving the interstitial part aside. This optimized ICstudy plan was not used clinically (image 6). We compared dose volume histogram (DVH) parameters, dose distributions, and source loading patterns of the ICstudy and the IC/ISclinical treatment plans. Each applied needle was evaluated: we registered the number of needles, and insertion depths. We registered the source dwell times for all active source and dwell positions of the IC/ISclinical plan. The total and individual needle treatment times per application were calculated and compared with the treatment times of tandem and ovoids.

**Follow-up**
Follow-up investigations were carried out 6 and 12 weeks after the last treatment and at 3 months intervals thereafter. Response to treatment was evaluated by clinical examination and by appropriate imaging studies (MRI, CT) 3 months after completion of radiotherapy. Acute side effects of treatment were assessed at least weekly during treatment and late side effects were assessed at time of each follow-up evaluation.
Statistical analyses
Statistical analyses were conducted using IBM SPSS Statistics 23.0. Patient and treatment characteristics were analyzed using descriptive statistics. The dosimetric differences between the optimized IC\textsubscript{study} plans and the optimized IC/IS\textsubscript{clinical} plans were calculated for HR-CTV and OARs.

Results:

Patients, tumor and treatment characteristics
The clinical use of the hybrid application system was clinically feasible in the eight patients. The average age was 47.7 years (25-68 years), three patients had stage IIB according to the FIGO 2010 classification, three patients had stage IIIB and two patients had stage IVA. All patients received concomitant radio chemotherapy with a total external radiotherapy dose of 46 Gy on the pelvis, 2 Gy per fraction, 5 fraction per week, using a 3D conformal technique, combined with weekly 40 mg/m\textsuperscript{2} cis-platinum chemotherapy, no patients received external parametrial boost irradiation. (table 1).

Evaluation
The evaluation of the response after the end of the concomitant radio chemotherapy was double clinical and radiological by MRI. The clinical size of the tumor residue varied between 3 and 6.2 cm in the major axis with an average of 4.4 cm. Four patients received an MRI the day before the first BT session and three patients received an MRI on the day of the first treatment applicator in place.

Brachytherapy technique
The high dose rate brachytherapy (HDR) protocol used was 4x7 Gy in two applications spaced one week apart. The applicator used is Utrecht interstitial or Fletcher interstitial 6mm. Four to eight needles were placed per fraction and a total of 152 needles were used for all applications. The choice of number and position of needles was based on the topography of the tumor residue on the MRI and the extent of parametrial infiltration. A suprapubic and endorectal ultrasound exam was performed during the insertion in four patients. Contouring of target volumes is done on MRI in 3 patients and on CT for the other 5 patients, dosimetry is done on CT. (image 6)

Plan comparison
The average CTV HR volume is 25.15 cc (15-36cc). A single IC\textsubscript{study} treatment plan generated for each application is used to make a dosimetric comparison with the constraints of the hybrid application (IC / IS). Significant differences between the IC / IS and IC alone plans were noted: the mean CTV HR D90 was 90.1 Gy (IS/IC\textsubscript{study}) vs 85.36 Gy (IC\textsubscript{study}) in EQ2D with α / β of 10. From even, the saving of the organs at risk differed significantly, for the bladder the D2cc is 82.5 Gy (IC / IS) vs 95.7 Gy (IC) and for the rectum D2cc is 65.5 Gy (IC / IS) vs 67.8 Gy (IC) in EQ2D with α / β of 3. (table 2)

Follow-up and Clinical results
The follow-up of the patients did not show a local recurrence with an average follow-up of 26.5 months (15-35 months), three patients experienced distant metastasis two of them died, treatment was well tolerated no bleeding or perforation of organ was noted, only one patient developed rectovaginal fistula.

Discussion:
MRI-based BT is well established in the treatment of cervical cancer and should be considered clinical standard. Improved imaging allows for a better delineation of target volumes and OARs. More sophisticated delineation frequently results in complex-shaped target volumes that require elaborate means of dose tailoring. However, even with dose optimisation, the CTV\textsubscript{HR} dose coverage may be compromised when using IC BT in case of large tumours or unfavorable topography between the CTV\textsubscript{HR} and organs at risk [10].

Historically, various interstitial needle placement techniques have been performed, ranging from free hand to template guided. These were introduced to improve treatment and to reduce local failures in patients with extensive parametrial disease. To date, transperineal template techniques remain the most frequently used methods for interstitial treatment in such cases. However, the main impediments to general acceptance of these methods are: difficulty in achieving accurate positioning of the implant and a good parallelism of the needles, and considerable risk of serious complications (11,12,13).
The use of a hybrid applicator combining IC and IS BT is the best “all-in-one” technical solution available to date and facilitate the implementation of the combined BT in centers without special expertise in free-hand or perineal template-based IS BT.

When using IC/IS applicators, the ovoide serves as a “template” and provides a fixed geometry between the tandem and the needles. The “template” (ovoide), as compared with the perineal techniques, lies in proximity to the parametria and thus to the target, resulting in a shorter interstitial path of the needles.

In our study the use of the IC/IS applicators proved to be feasible, we note a prolongation of time needed for implantation and treatment planning, compared with ICBT alone. Moreover, no severe injuries were caused by the implantation procedure. No considerable prolongation of hospitalization time, as compared with ICBT alone. This technique translated into good regional local control in our study.

The actual indication of ICBT, hybrid BT (HBT), and multi-catheter ISBT is a challenging topic which needs clinical experience in order to select the most appropriate brachytherapy modality depending on tumor size and shape [13]. Whatsoever, in our study lateral tumor extent with parametrial involvement or large residual disease was well controlled with HBT.

The number of needles, maximum insertion depth, weight of the needle dwell times compared with other applicator parts, loading pattern in needles, and placement of the needle tip in relation with HR-CTV are still subjects of investigation. Our institutional choices are based on international and institutional experiences and discussions.

Only mono- institutional studies have so far reported clinical outcome of patient cohorts where the IC/IS technique has been systematically applied [14,15]

Our study is in line with the Vienna applicator data (16), Utrecht applicator dose data (17), and the Venezia applicator data (18). The dosimetric gain in our situation for D90 HR-CTV was 4.74 Gy, for the Vienna applicator a total benefit in dose of 9 Gy has been published, for the Utrecht publication a 4,4 Gy dosimetric gain was noted and for venezia applicator data the dosimetry gain was 9,9 Gy.

A recent analysis from the retroEMBRACE cohort enhanced the importance of meticulous dose tailoring. The study included 610 patients from eight institutions and was able to show that with the systematic use of a combined IC/IS BT, the D90 of HR-CTV significantly increased (83 Gy vs92 Gy; p=0.01) with no difference in doses to OARs. Fokdal et al. could demonstrate that this was even correlated with an increase of 3-year local control rate in patients with a large HR-CTV volume (30 cm³) [19].

Conclusion:-
Combined IC/IS BT makes it possible to deliver significantly higher dose to the CT-HR without increasing the dose to bladder, rectum or sigmoid. These dosimetric findings result improved therapeutic index with significantly higher local control for large high-risk target volumes without adding further late bladder, or gastro- intestinal morbidity to treatment.

Table 1:- Patient and treatment characteristics.

| Age                  | 47.7 years (25-68 years) |
|----------------------|--------------------------|
| Histology            | SQUAMOUS CELL CARCINOMA (100%) |
| Initial stage (FIGO2010) | IIB: 3 cases |
|                      | IIB: 3 cases |
|                      | IVA: 2 cases |
| Concomitant radio-chemotherapy (CRC) | EBRT: 46 Gy, 2 Gy/Fr, 23 fractions |
|                      | CHEMOTHERAPY: CDDP 40mg/m2/week |
| Clinical evaluation after CRC | Vaginal exam = tumor residue 4.4cm (3 - 6.2 cm) |
|                      | Rectal exam = Distal parametrial involvement in all patients |
| Radiological evaluation after CRC | MRI after CRC |
5 cases: the week before the implant
3 cases: the day of application with applicator in place

**Brachytherapy protocol**
4x7 Gy in two applications spaced a week apart

**Applicator**
50 % Fletcher interstitial 6 mm
50 % Utrecht interstitial

**Needles**
5 by application (4-8)

**Depth (median)**
4 cm (3 – 5 cm)

**Ultrasound control**
50% of cases

**Target volume delineation**
MRI: 3 cases
CT: 5 cases

**CTV HR volume**
25.15 cc (15 - 36 cc)

**Dosimetry**
CT

**Dwell times IC (average)**
24,58 sec (9,35 - 41,33)

**Dwell times IS (average)**
2,3 sec (1,23 - 4)

**Follow up (average)**
27,25 months (range 18–34).
No local relapse
3 distant metastases (2 Deaths)

**Acute complications**
1 case of intra-mural uterine hematomata

**Late complications**
1 case of recto-vaginal fistula

| Table 2:— Plan evaluation for DVH parameters of CTV HR and OARs. |
|---------------------------------------------------------------|
| **EQD2 (Gy)** | **IC/IS** | **IC study** |
|                | AVERAGE   | INTERVAL    | AVERAGE | INTERVAL   |
| **D90 CTV HR (α/β 10)** | 90,1 | 80,4-92,8 | **85,36** | 72,3-91,4 |
| **D90 CTV IR(α/β 10)** | 67,4 | 65,1-69,5 | 57,6 | 54,4-61,4 |
| **D2cc BLADDER (α/β 3)** | **82,5** | 67,8-90,7 | **95,7** | 83,7-113,1 |
| **D2cc RECTUM (α/β 3)** | 65,5 | 61,3-72,6 | **67,8** | 58,3-75,2 |
| **D2cc SIGMOIDE (α/β 3)** | 62,2 | 53,2-76,5 | 60,8 | 52,1-67,2 |
| **D2cc BOWELL (α/β 3)** | 60,4 | 51,5-73,2 | 60,5 | 55-70,5 |

**Image 1:**— Utrecht interstitial CT/MRI applicator (Nucletron, Veenendaal, The Netherlands).
Image 2:- The holes through ovoids are used as a template for interstitial needle placement.

Image 3:  
T2-weighted sagittal MRI to assess treatment response  
A: before initial treatment  
B: during the last week of EBRT

Image 4:- T2-weighted transverse MRI showing applicator in place with ovoids and inserted needles.

Image 5: Combined intracavitary and interstitial brachytherapy technique
1: Spinal anesthesia  
2: material preparation with asepsis  
3: Placement of a urinary catheter and hysterometry,  
4,5,6,7: assembly of the interstitial applicator: metal guide, needle holder and needle in the ovoids positions  
8: Vaginal applicator is then fixed with the uterine tandem, and introduced into the vagina  
9: Using a special gun, we introduce the needles according to the chosen depth
10, 11: Ultrasound check: position of the tandem, needles and search for complications (bladder perforation)
12: numbering of needles position

Image 6:
CT scanner showing CTV HR extension (green), 100% isodose (red), inserted needles, and OARs
A: IC study plan without activation of needles
B: IC/IS clinical plan with activation of needles
1. IC/IS BT: intracavitary/interstitial brachytherapy
2. MRI: magnetic resonance imaging
3. CT: computed tomography
4. HDR BT: high-dose-rate brachytherapy
5. CTV HR: high-risk clinical target volume
6. EBRT: external-beam radiotherapy
7. IGABT: image-guided adaptive brachytherapy
8. OAR: organs at risk
9. DVH: dose volume histogram
10. FIGO: international federation of gynecology and obstetrics
11. HBT: hybrid BT

Ethics approval and consent to participate:
Informed consent (verbal) was obtained from all participants. This study was submitted to and approved by research and ethics committee of the national institute of oncology of Rabat.

Competing interests:
We (authors) declare that we have no conflict of interest.

Acknowledgement:
All the authors are thankful for providing the necessary facilities for the preparation the manuscript. Special thanks are due to the Faculty of Medicine and Pharmacy of Rabat; the source(s) of funding for all authors

Bibliography:
1. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340: 1137–1143.
2. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340:1144–1153.
3. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjuvant chemoradiation in stage IB–IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17:1339–1348.
4. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemoradiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001; 8:358:781–786.
5. Dimopoulos J, Pötter R, Kirisits C, et al. Impact of systematic MRI assisted treatment planning on local control in cervix cancer: Vienna Experience in 145 patients treated by intracavitary interstitial brachytherapy from 1998–2003 [Abstract]. Int J Radiat Oncol Biol Phys 2005;63(Suppl.1):S219–S220.
6. Gerbaulet A, Pötter R, Haie-Meder C. Cervix cancer. The GEC ESTRO handbook of brachytherapy. Brussels: European Society of Therapeutic Radiology and Oncology; 2002. p 300–363.
7. Subak LL, Hricak H, Powell CB, et al. Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstet Gynecol 1995; 86:43e50.
8. Haie-Meder C, Potter R, Van Limbergen E, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): Concepts and terms in 3D image-based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005; 74:235e245.
9. Potter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy: 3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 2006; 78:67e77.
10. Kirisits C, Lang S, Dimopoulos J, Berger D, Georg D, Potter R. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: design, application, treatment planning, and dosimetric results. Int J Radiat Oncol Biol Phys 2006;65:624–30.
11. Hughes-Davies L, Silver B, Kapp DS. Parametrical interstitial brachytherapy for advanced or recurrent pelvic malignancy: the Harvard/Stanford experience. Gynecol Oncol 1995; 58:24–27.
12. Aristizibal SA, Surwit EA, Hevezi JM, Heusinkveld RS. Treatment of advanced cancer of the cervix with transperineal interstitial irradiation. Int J Radiat Oncol Biol Phys 1983;9: 1013–1017.

13. Monk BJ, Tewariu K, Burger RA, et al. A comparison of intracavitary versus interstitial irradiation in the treatment of cervical cancer. Gynacol Oncol 1997; 67:241–247.

14. Lindegaard JC, Fokdal LU, Nielsen SK, Juul-Christensen J, Tanderup K. MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective. Acta Oncol 2013;52:1510–9.

15. Pötter R, Dimopoulos J. Clinical outcome of protocol-based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. RadiotherOncol 2011;100:116–23.

16. Dimopoulos JC, Kirisits C, Petric P, et al. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: Clinical feasibility and preliminary results. Int J Radiat Oncol Biol Phys 2006; 66:83–90.

17. Nomden CN, de Leeuw AA, Moerland MA, et al. Clinical use of the Utrecht applicator for combined intracavitary/interstitial brachytherapy treatment in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2012; 82:1424e1430.

18. Franziska Walter et al, Combined intracavitary and interstitial brachytherapy of cervical cancer using the novel hybrid applicator Venezia: Clinical feasibility and initial results Brachytherapy (2018)

19. Fokdal L, Sturdza A, Mazeron R, et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. RadiotherOncol 2016; 120:434e440.